<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309478</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-5</org_study_id>
    <nct_id>NCT00309478</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients</brief_title>
  <official_title>A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil Vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-Positive, Lymph Node-Positive or -Negative Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <brief_summary>
    <textblock>
      Primarily, this clinical investigation compared the efficacy of cyclophosphamide +
      methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of
      prognosis (disease-free survival, overall survival) in premenopausal patients with
      potentially curative, operated hormone receptor-positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1990</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <enrollment>1099</enrollment>
  <condition>Early-Stage Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal patients with histologically verified, lymph node-negative (pT1c-pT3) or
             lymph node-positive (pT1a-pT3) breast cancer

          -  Hormone receptor-positive status

          -  More than 6 histologically examined lymph nodes

          -  Laboratory parameters

               1. hematopoiesis: &gt; 3500/l leukocytes, &gt; 100,000/l thrombocytes

               2. renal function: creatinin &lt; 1.5mg%

               3. hepatic function: GOT &lt;/= 2.5 x UNL

               4. bilirubin: &lt; 1.5mg %

               5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar

               6. blood coagulation: PZ &gt; 60%

          -  Concluded healing process following surgery

          -  &lt;/= 4 weeks interval since surgery

          -  Informed consent

        Exclusion Criteria:

          -  T4 carcinoma; inflammatory breast cancer, carcinoma in situ

          -  Simultaneous or sequential bilateral breast cancer

          -  Preoperative tumor-reducing radiotherapy or preoperative tumor-specific medical
             treatment

          -  Male patients

          -  Pregnancy or lactation

          -  Lacking compliance or understanding of the disease

          -  General contraindication against cytostatic treatment

          -  Serious concomitant disease preventing implementation of adjuvant therapy or regular
             follow-up

          -  Second carcinoma or status post second carcinoma (except for curatively treated
             squamous cell carcinoma of the skin or cervical carcinoma in situ)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Jakesz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <link>
    <url>http://www.abcsg.at</url>
  </link>
  <verification_date>June 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>May 18, 2006</last_update_submitted>
  <last_update_submitted_qc>May 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2006</last_update_posted>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Goserelin</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Breast cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

